Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

European Journal of Haematology

Volumn 85, Issue 3, 2010, Pages 231-235

  Oliva, Esther N ^a   Cuzzola, Maria ^a   Nobile, Francesco ^a   Ronco, Francesca ^a   D'Errigo, Maria Grazia ^a   Laganà, Carmelo ^a   Morabito, Fortunato ^b   Galimberti, Sara ^c   Cortelezzi, Agostino ^d   Aloe Spiriti, Maria A ^e   Specchia, Giorgina ^f   Poloni, Antonella ^g   Breccia, Massimo ^h   Ghio, Riccardo ⁱ   Finelli, Carlo ^j   Iacopino, Pasquale ^a   Alimena, Giuliana ^h   Latagliata, Roberto ^h  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b Azienda Ospedaliera di Cosenza   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

del(5Q); lenalidomide; myelodysplastic syndromes; RPS14

Indexed keywords

HEMOGLOBIN; LENALIDOMIDE; RIBOSOMAL PROTEIN S14; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; RPS14 PROTEIN, HUMAN; THALIDOMIDE;

5Q- SYNDROME; AGED; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; ERYTHROID CELL; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHROMOSOME 5; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; PHASE 2 CLINICAL TRIAL; RISK FACTOR;

AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CYTOGENETIC ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; RIBOSOMAL PROTEINS; RISK FACTORS; THALIDOMIDE; TRANSCRIPTION, GENETIC;

EID: 77955812835     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01473.x     Document Type: Article

References (15)

1. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008 93 : 1712 7.
2. Mohamedali A, Mufti GJ. Van-den Berghe's 5q- syndrome in 2008. Br J Haematol 2009 144 : 157 68.
3. Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 2009 115 : 5202 9.
4. Pellagatti A, Esoof N, Watkins F, et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 2004 125 : 576 83.
5. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34 + cells in patients with the 5q- syndrome. Br J Haematol 2007 139 : 578 89.
6. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008 451 : 335 9.
7. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010 16 : 59 66.
8. Czibere A, Bruns I, Junge B, Singh R, Kobbe G, Haas R, Germing U. Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica 2009 94 : 1453 5.
9. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005 352 : 549 57.
10. List A, Dewald G, Bennett J, et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 355 : 1456 65.
11. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 89 : 2079 88.
12. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006 108 : 419 25.
13. Shaffer LG, Tommerup N. An International System for Human Cytogenetic Nomenclature.
14. Garderet L, Kobari L, Mazurier C, Hurtrelle C, Giarratana MC, Perot C, Gorin NC, Lapillonne H, Douay H. Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study. Haematologica, doi :.
15. Pellagatti A, Jädersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci 2007 104 : 11406 11.